Welcome to our dedicated page for DOCGO SEC filings (Ticker: DCGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DocGo Inc. filings document the company’s mobile health, medical transportation and virtual care business, along with formal disclosures on operating results, governance, listing compliance and capital allocation. Form 8-K reports include quarterly and annual earnings releases, non-GAAP measures such as adjusted gross margin and adjusted EBITDA contribution margin, share repurchase program disclosures, and Nasdaq minimum bid price compliance matters.
Proxy materials cover director elections, advisory executive compensation votes and capital-structure proposals. Other filings record board and committee changes, special committee formation, shareholder voting matters, material-event disclosures and common-stock structure for the Nasdaq-listed issuer.
DocGo Inc. reported fourth quarter and full-year 2025 results, raised its 2026 outlook, and began exploring strategic alternatives to maximize shareholder value. Full-year 2025 revenue was $322.2 million, down from $616.6 million in 2024 entirely due to the wind-down of migrant-related programs, which fell from $373.5 million to $69.6 million. Excluding these programs, core businesses grew, including Medical Transportation revenue rising to $200.8 million and Mobile Health Services reaching $121.4 million. The company swung to a 2025 net loss of $196.4 million, including non-cash impairments of $30.6 million in intangible assets, $58.2 million in goodwill, and $5 million on an equity investment. Adjusted EBITDA shifted from a $60.3 million profit in 2024 to a $28.6 million loss in 2025. In the fourth quarter, revenue was $74.9 million and adjusted gross margin was 32.5%. Cash and cash equivalents, including restricted cash and investments, totaled about $68.3 million as of December 31, 2025. For 2026, DocGo now expects revenue of $290–$310 million with an adjusted EBITDA loss of $5–$10 million, improved from prior guidance, and management believes profitability is achievable in the second half of 2026.
DocGo Inc. investor Stanley Vashovsky filed Amendment No. 2 to his Schedule 13D, showing a sharp reduction in his ownership. He now beneficially owns 241,348 shares of common stock, or 0.2% of the class, based on 97,813,372 shares outstanding as of November 7, 2025.
Vashovsky originally received over 13.1 million shares through the Ambulnz merger and additional equity awards for his service as Chief Executive Officer, non-executive Chair, and consultant. Between 2022 and February 24, 2026, he gifted multiple large blocks of stock to estate-planning and charitable trusts, including 4,914,451 shares to a not-for-profit organization, leaving him below the 5% beneficial ownership threshold.
DocGo Inc. has been notified by Nasdaq that its stock no longer meets the exchange’s $1.00 minimum bid price requirement. Nasdaq reviewed closing bid prices between December 9, 2025 and January 23, 2026 and found the shares below the threshold, triggering a compliance notice.
The company keeps its current Nasdaq Capital Market listing for now and has until July 27, 2026 to lift its closing bid to at least $1.00 for ten consecutive business days. If it still falls short, DocGo may seek a second 180-day grace period, potentially including a reverse stock split to restore compliance.
DocGo Inc.'s Chief Executive Officer and director Lee Bienstock reported equity awards and related tax withholding transactions in the company’s common stock. On December 12, 2025, he received 1,113,495 restricted stock units (RSUs) under DocGo’s 2021 Stock Incentive Plan, which will vest in four equal annual installments on each of the first four anniversaries of December 12, 2025. Each RSU entitles him to receive one share of DocGo common stock upon vesting.
On December 15, 2025, 214,131 RSUs were withheld at a price of $0.91 per share to satisfy his tax liability from RSUs granted on December 12, 2023 and December 12, 2024. After these transactions, Bienstock beneficially owns 2,836,281 shares of DocGo common stock directly, including previously granted RSUs scheduled to vest on various dates between March 28, 2026 and December 12, 2028 under the plan.
DocGo Inc.'s CFO and Treasurer, Norman Rosenberg, reported equity compensation and related tax withholding transactions. On December 12, 2025, he received 429,405 restricted stock units (RSUs) under DocGo’s 2021 Stock Incentive Plan at a stated price of $0, bringing his beneficial ownership to 1,289,345 shares of common stock.
On December 15, 2025, 65,774 shares were withheld at $0.91 per share to cover his tax liability from earlier RSU grants, reducing his beneficial ownership to 1,223,571 shares. The new RSUs vest in four equal annual installments on each of the first four anniversaries of December 12, 2025, and additional previously granted RSUs are scheduled to vest between December 2026 and December 2028.
DocGo Inc.'s chief compliance officer, Stephen Sugrue, reported new equity awards and related tax withholding. On December 12, 2025, he received 321,055 restricted stock units (RSUs) under the 2021 Stock Incentive Plan, vesting in four equal annual installments starting on the first anniversary of that date. Each RSU represents the right to receive one share of common stock upon vesting.
On December 15, 2025, 35,968 RSUs were withheld at a price of $0.91 per share to satisfy his tax liability from earlier RSU grants. After these transactions, Sugrue beneficially owns 636,602 shares of DocGo common stock, including additional RSUs scheduled to vest between December 2026 and December 2028.
DocGo Inc. reported that director and officer Ely D. Tendler received 100,000 restricted stock units on December 12, 2025 under the company’s 2021 Stock Incentive Plan. These units vest in four equal annual installments on each of the first four anniversaries of that date, with each unit delivering one share of common stock when it vests.
On December 15, 2025, Tendler sold 16,850 shares of common stock at $0.91 to cover taxes due on vested units from earlier grants made in 2023 and 2024. After these transactions, he beneficially owned 258,795 DocGo shares and restricted stock units in total, including additional awards scheduled to vest in 2026 and 2027.
DocGo Inc. director Michael J. Burdiek received 150,000 shares of common stock in the form of restricted stock units (RSUs) on December 12, 2025. These RSUs were granted at a price of $0 under DocGo's 2021 Stock Incentive Plan and are scheduled to vest on December 12, 2026, subject to the plan's terms. Each RSU represents the right to receive one share of DocGo common stock upon vesting. Following this grant, Burdiek beneficially owns 791,560 shares of DocGo common stock directly.
DocGo Inc. director Etalvina Leite received an equity award in the form of restricted stock units. On December 12, 2025, Leite was granted 150,000 restricted stock units of DocGo common stock at a grant price of $0 under the company’s 2021 Stock Incentive Plan. These RSUs are scheduled to vest on December 12, 2026, and each unit will convert into one share of common stock upon vesting, subject to the plan’s terms. Following this award, Leite beneficially owns 201,411 shares of DocGo common stock, held directly.